GlassScriptPhysician profile
James H Sullivan
NPI 1164521142
$1,482.93
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,100 · 2020: $214 · 2021: $73.16 · 2022: $80.66 · 2023: $15.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $799.37 | 2019-2022 | |
| Medtronic USA, INC. | $88.42 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $85.01 | 2019-2020 | |
| Pfizer INC. | $81.85 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $78.10 | 2019-2020 | |
| Boston Scientific Corporation | $71.15 | 2019 | |
| Medtronic, INC. | $51.06 | 2021-2022 | |
| Horizon Therapeutics Plc | $40.52 | 2019-2021 | |
| Abbott Laboratories | $27.96 | 2020-2022 | |
| Biodelivery Sciences International, INC. | $24.55 | 2019-2020 | |
| Abbvie INC. | $21.30 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.23 | 2019 | |
| Amgen INC. | $18.51 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $17.68 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.21 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $15.21 | 2023 | Qutenza |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.27 | 2020 | |
| Si-Bone, INC. | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.